Company Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.
The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis.
RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
| Country | Israel |
| Founded | 2009 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 53 |
| CEO | Dror Ben-Asher |
Contact Details
Address: 21 Ha'arba'a Street Tel Aviv, L3 64739 Israel | |
| Phone | 972-3-541-3131 |
| Website | redhillbio.com |
Stock Details
| Ticker Symbol | RDHL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001553846 |
| CUSIP Number | 757468103 |
| ISIN Number | US7574682024 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dror Ben-Asher | Co-Founder, Chairman and Chief Executive Officer |
| Razi Ingber | Chief Financial Officer |
| Gilead Raday MPhil, MSc | Chief Operating Officer |
| Adi Frish | Chief Corporate and Business Development Officer |
| Rick D. Scruggs | Chief Commercial Officer, President of RedHill Biopharma Inc. and Director |
| Alexandra Okmian | Senior Business Development and Investor Relations Manager |
| Dr. Reza Fathi Ph.D. | Senior Vice President of Research and Development |
| Guy Goldberg J.D. | Chief Business Officer |
| Dr. June S. Almenoff FACP, M.D., Ph.D. | Chief Medical Officer |
| Patricia Anderson B.Sc. RAC | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2024 | 6-K | Report of foreign issuer |
| Apr 22, 2024 | EFFECT | Notice of Effectiveness |
| Apr 18, 2024 | POS AM | Post-Effective amendments for registration statement |
| Apr 8, 2024 | 6-K | Report of foreign issuer |
| Apr 8, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Apr 4, 2024 | 6-K | Report of foreign issuer |
| Apr 3, 2024 | 6-K | Report of foreign issuer |
| Apr 2, 2024 | 424B5 | Filing |
| Apr 2, 2024 | 6-K | Report of foreign issuer |
| Mar 21, 2024 | 6-K | Report of foreign issuer |